z-logo
open-access-imgOpen Access
Engineering 3D Printed Microfluidic Chips for the Fabrication of Nanomedicines
Author(s) -
Aytug Kara,
Athina Vassiliadou,
Baris Őngoren,
William Keeble,
Richard Hing,
Aikaterini Lalatsa,
Dolores R. Serrano
Publication year - 2021
Publication title -
pharmaceutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 50
ISSN - 1999-4923
DOI - 10.3390/pharmaceutics13122134
Subject(s) - stereolithography , materials science , microfluidics , nanotechnology , 3d printing , 3d printed , nanomedicine , nanoparticle , fused deposition modeling , biomedical engineering , composite material , engineering
Currently, there is an unmet need to manufacture nanomedicines in a continuous and controlled manner. Three-dimensional (3D) printed microfluidic chips are an alternative to conventional PDMS chips as they can be easily designed and manufactured to allow for customized designs that are able to reproducibly manufacture nanomedicines at an affordable cost. The manufacturing of microfluidic chips using existing 3D printing technologies remains very challenging because of the intricate geometry of the channels. Here, we demonstrate the manufacture and characterization of nifedipine (NFD) polymeric nanoparticles based on Eudragit L-100 using 3D printed microfluidic chips with 1 mm diameter channels produced with two 3D printing techniques that are widely available, stereolithography (SLA) and fuse deposition modeling (FDM). Fabricated polymeric nanoparticles showed good encapsulation efficiencies and particle sizes in the range of 50–100 nm. SLA chips possessed better channel resolution and smoother channel surfaces, leading to smaller particle sizes similar to those obtained by conventional manufacturing methods based on solvent evaporation, while SLA manufactured nanoparticles showed a minimal burst effect in acid media compared to nanoparticles fabricated with FDM chips. Three-dimensional printed microfluidic chips are a novel and easily amenable cost-effective strategy to allow for customization of the design process for continuous manufacture of nanomedicines under controlled conditions, enabling easy scale-up and reducing nanomedicine development times, while maintaining high-quality standards.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom